News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Joe Y. Chang on upcoming PTCOG 63: IMRT vs IMPT Phase III trials
Joe Y. Chang/X
May 21, 2025, 18:49

Joe Y. Chang on upcoming PTCOG 63: IMRT vs IMPT Phase III trials

Joe Y Chang, Professor, Clinical Section Chief at MD Anderson Cancer Center, shared a post on X:

“Join us at PTCOG 63 to explore cutting-edge particle therapy and novel Phase III randomized studies comparing IMRT and IMPT.
With advancements in LET optimization, immune modulation, we are moving PT into the new era.”

PTCOG 63

More posts featuring Joe Y Chang on OncoDaily.

cancer IMPT IMRT Joe Y Chang MD Anderson Cancer Center OncoDaily Oncology PTCOG 63
Special Coverage
Insight
May 21, 2025, 18:49
Joe Y. Chang on upcoming PTCOG 63: IMRT vs IMPT Phase III trials
Blog
May 21, 2025, 18:11
Poland’s Cancer Landscape at Cancer Mission Fair - European Cancer Organisation
Insight
May 21, 2025, 18:05
Goutham Sunny on KRAS G12C inhibition in non-small cell lung cancer
Blog
May 21, 2025, 18:02
Tackling Information Overload in Cancer Research - Train at NCI
Societies
May 21, 2025, 17:54
Patrick Hwu: Kicked off the 2025 Scientific Symposium at Moffitt Cancer Center
Blog
May 21, 2025, 17:54
Applications are Open for the Basic Principles in Oncology Course - European School of Oncology
Career
May 21, 2025, 17:46
Sharon Kapambwe Has Been Appointed as Technical Officer for Cancer Control at WHO Uzbekistan
Opinion
May 21, 2025, 17:41
Bishal Gyawali addressed G7 cancer drug approval claims about Canada with the Lancet Oncology Study
Blog
May 21, 2025, 17:33
From Lung Cancer Risk to Response - UICC
Blog
May 21, 2025, 17:25
Rick Buck Presents on AACR Collaboration at Cancer Marketing and Communications Association Meeting
Insight
May 21, 2025, 17:20
Lung Cancer Europe shared study on short-term prehabilitation in resectable NSCLC patients
Insight
May 21, 2025, 17:12
Tanja Obradovic: Issue of Trial Data Applicability to US Patient Population is Resurfacing Again at FDA